Y Intercept Hong Kong Ltd Purchases Shares of 34,485 Qiagen N.V. $QGEN

Y Intercept Hong Kong Ltd purchased a new position in shares of Qiagen N.V. (NYSE:QGEN) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 34,485 shares of the company’s stock, valued at approximately $1,381,000.

Other hedge funds have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its position in Qiagen by 10.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 3,164,805 shares of the company’s stock worth $143,018,000 after purchasing an additional 290,449 shares during the period. Vanguard Group Inc. boosted its position in Qiagen by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,542,944 shares of the company’s stock valued at $433,871,000 after buying an additional 118,135 shares during the period. Moors & Cabot Inc. boosted its position in Qiagen by 78.2% during the third quarter. Moors & Cabot Inc. now owns 352,809 shares of the company’s stock valued at $15,764,000 after buying an additional 154,851 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Qiagen by 1.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 24,205,881 shares of the company’s stock valued at $1,088,538,000 after buying an additional 264,921 shares during the last quarter. Finally, Perbak Capital Partners LLP increased its holdings in shares of Qiagen by 78.2% in the third quarter. Perbak Capital Partners LLP now owns 104,838 shares of the company’s stock worth $4,684,000 after buying an additional 46,002 shares during the period. 70.00% of the stock is currently owned by institutional investors.

Qiagen Trading Down 1.1%

NYSE:QGEN traded down $0.47 during mid-day trading on Friday, reaching $41.52. 3,565,122 shares of the company’s stock traded hands, compared to its average volume of 2,901,811. The company has a 50 day moving average price of $36.59 and a 200-day moving average price of $42.60. The firm has a market capitalization of $8.56 billion, a price-to-earnings ratio of 21.68, a PEG ratio of 4.19 and a beta of 0.64. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57. Qiagen N.V. has a 12-month low of $32.53 and a 12-month high of $57.81.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.54 earnings per share for the quarter, hitting the consensus estimate of $0.54. The business had revenue of $492.32 million during the quarter, compared to analysts’ expectations of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same quarter last year, the business posted $0.56 EPS. On average, sell-side analysts predict that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Tuesday, July 14th. Investors of record on Tuesday, July 7th will be paid a $0.35 dividend. The ex-dividend date of this dividend is Tuesday, July 7th. This is a positive change from Qiagen’s previous annual dividend of $0.26. This represents a yield of 90.0%. Qiagen’s payout ratio is 18.32%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on QGEN. Wall Street Zen lowered Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Barclays set a $38.00 price target on Qiagen and gave the stock an “equal weight” rating in a research report on Wednesday, April 29th. JPMorgan Chase & Co. decreased their price target on Qiagen from $60.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th. Stifel Nicolaus set a $36.00 price objective on Qiagen and gave the company a “hold” rating in a research report on Monday, May 18th. Finally, TD Cowen reissued a “hold” rating and set a $40.00 price objective (down from $46.00) on shares of Qiagen in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $43.15.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.